期刊文献+

骨质疏松症治疗药物的合理应用 被引量:4

原文传递
导出
摘要 骨质疏松症是一种骨强度降低而导致骨脆性增加、易发生骨折为特征的全身性代谢性骨病。由于人们对骨质疏松症的严重后果认识不足、早期症状和危险因素识别不清、诊断治疗率低,甚至临床治疗策略也常存在误区或盲区,这些都可能延误患者有效的治疗时机,从而造成治疗效果不理想、反复骨折、致残率高、生活质量差、螺钉松动及内固定不稳等严重后果。因单一抗骨质疏松症药物并非能够贯穿整个疾病始终,坚持长程序贯治疗尤为重要,同时非必要不推荐同种作用机制药物联合使用。只有在临床上关注骨质疏松症治疗的这些问题,才能促进骨质疏松症治疗药物的合理应用。
出处 《中华医学杂志》 CAS CSCD 北大核心 2022年第25期1941-1944,共4页 National Medical Journal of China
  • 相关文献

参考文献5

二级参考文献49

  • 1Cosman F1, de Beur SJ, LeBoff MS, et al. Clinician's Guide to Prevention and Treatment of Osteoporosis [ J ]. Osteoporos Int. 2014, 25: 2359-2381.
  • 2Kanis JA, McCloskey EV, Johansson H, et aL European guidance for the diagnosis and managementof osteoporosis in postmenopausal women [ J]. Osteoporoslnt, 2013, 24: 23-57.
  • 3Solomon DH, Avorn J, Katz JN, et al. Compliance with osteoporosis medications [ J ]. Arch Intern Med, 2005, 165 : 2414-2419.
  • 4Briot K, Cortet B, Thomas T, et al. 2012 update of french guidelines for the pharmacological treatment of postmenopa- usal osteoporosis [J]. Joint Bone Spine, 2012, 79: 304-313.
  • 5Klotzbuecher CM, Ross PD, Landsman PB, et al. Patients with prior fractures have an increased risk of future frac- tures: a summary of the literature and statistical synthesis[J]. J Bone Miner Res, 2000, 15: 721-739.
  • 6Confavreux CBI, Paccou 1, David C, et al. Defining treatment failure in severe osteoporosis [ J ]. Joint Bone Spine, 2010, 77 (Suppl 2) : S128-S132.
  • 7Watts NB, Bilezikian JP, Camacho PM, et al. American Association of Clinical Endocrinologists Medical Guide- lines for Clinical Practice for the diagnosis and treatment of postmenopausal osteoporosis [J]. Endo Prac, 2010, 16 (Suppl 3) : 1-37.
  • 8Division of Metabolic and Endocrine Drug Products Food and Drug Administration. Guidelines for preclinical and clinical evaluation of agents used in the prevention or treatment of postmenopausal osteoporosis [ EB/OL ]. [ 1994-05-28 ]. http: //www. fda. gov/OHRMS/DOCK- ETS/98fr/O4d-O035- gdl0001, pdf.
  • 9Cheng XG, Nicholson PH, Boonen S, et al. Prediction of vertebral strength in vitro by spinal bone densitometu and calcaneal uhrasound [J]. Bone Nliner B_es, 1997, 12 : 1721-1728.
  • 10Wasnich RD, Miller PD. Antifracture efficacy of antire- sorptive agents are related to changes in bone density [J]. J Clin Endocrinol Metab, 2000, 85: 231-236.

共引文献275

同被引文献58

引证文献4

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部